local_hospital

Osrodek Badan Klinicznych Przy Szpitalu Specjalistycznym Im. Ludwika Rydygiera W Krakowie Sp. z o.o.

Address
lock Available on a paid plan

Musculoskeletal Diseases and Pain Research

At Osrodek Badan Klinicznych Przy Szpitalu Specjalistycznym Im. Ludwika Rydygiera W Krakowie Sp. z o.o., clinical studies in musculoskeletal diseases focus on knee osteoarthritis and related chronic pain, with additional interest in weight-related joint burden. These trials are designed to test new symptom-relief options, improve daily function, and better understand treatment effectiveness for people living with long-term joint problems.

  • knee osteoarthritis and chronic pain management
  • overweight or obesity with joint symptoms
  • Evaluating therapies that may reduce pain and improve mobility

The site’s work in this area reflects a practical focus on easing discomfort and supporting movement in patients with common, disabling musculoskeletal conditions.

Cardiovascular Diseases and Thromboembolic Prevention

Research in cardiovascular diseases includes atrial fibrillation, stroke prevention, hypertension, heart failure, and venous thromboembolism. These studies aim to improve protection against clot-related events, reduce bleeding risk, and assess treatments that may help patients with high cardiovascular risk or established heart disease.

  • atrial fibrillation and prevention of cardioembolic events
  • acute ischemic stroke and high-risk transient ischemic attack
  • heart failure and hypertension management
  • Balancing effectiveness with safer anticoagulation strategies

This portfolio shows a strong interest in better prevention and treatment approaches for major cardiovascular conditions that affect long-term health.

Neoplasms and Cancer Therapy

A large share of the research at this clinical research site centers on neoplasms, including breast cancer, lung cancer, head and neck cancer, prostate cancer, pancreatic cancer, bladder cancer, melanoma, and several types of lymphoma and leukemia. The trials mainly explore new therapies, combination treatments, and ways to improve survival or control disease after prior treatment.

  • advanced or metastatic cancers across multiple tumor types
  • lung cancer, breast cancer, and head and neck squamous cell carcinoma
  • lymphoma and leukemia studies
  • Testing targeted, immune-based, and combination cancer treatments

Overall, the oncology program is broad and active, with studies aimed at improving outcomes for both newly diagnosed and previously treated patients.

Nervous System Diseases and Neurology Studies

Clinical trials in nervous system diseases include multiple sclerosis, myasthenia gravis, spinal muscular atrophy, and stroke-related conditions. The research is focused on easing symptoms, slowing disability progression, and exploring more effective ways to prevent neurological injury or relapse.

  • multiple sclerosis, including progressive and relapsing forms
  • myasthenia gravis symptom control
  • spinal muscular atrophy and treatment handling
  • Improving prevention and recovery after stroke

These studies support a wider effort to refine care for chronic neurological disorders that can significantly affect independence and quality of life.

Digestive System Diseases and Gastrointestinal Care

The site also participates in trials for digestive system diseases, especially colorectal cancer, Crohn-related fistula, and pancreatic disease, as well as post-surgical digestive problems such as pancreatic exocrine insufficiency and post-gastrectomy nutritional issues. These studies are intended to improve treatment response, symptom control, and nutritional support.

  • colorectal cancer and pancreatic cancer
  • Crohn’s disease-related fistula and bowel complications
  • post-gastrectomy digestive and nutritional care
  • Evaluating therapies that may improve digestion and overall patient support

This area combines cancer research with broader gastrointestinal care, reflecting a diverse set of digestive health priorities.

Hemic and Lymphatic Diseases Research

Studies in hemic and lymphatic diseases cover acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, and different forms of non-Hodgkin lymphoma and Hodgkin lymphoma. The main purpose is to assess new treatment combinations, improve remission rates, and support patients whose disease has returned or not responded to earlier therapy.

  • leukemia and lymphoma treatment strategies
  • multiple myeloma and immune support in blood cancers
  • Trials for relapsed or refractory disease
  • Testing therapies that may deepen response and extend disease control

The hematology program at the Krakow site is centered on improving care for complex blood cancers through innovative and comparative research.

Immune System Diseases and Autoimmune Disorders

Research in immune system diseases includes multiple sclerosis and other conditions where immune activity affects the nervous system or overall health. These trials aim to reduce disease activity, limit progression, and evaluate treatments that may offer better long-term control of immune-mediated illness.

  • multiple sclerosis treatment and disability progression
  • Immune-targeted approaches for chronic inflammatory disease
  • Assessing whether newer options improve disease control

The research reflects a continued effort to refine therapies for patients with persistent immune-related conditions.

Nutritional and Metabolic Diseases and Cachexia Studies

Trials in nutritional and metabolic diseases address obesity, cancer cachexia, and metabolic changes linked to chronic illness. The aim is to evaluate treatments that may help preserve body weight, support nutrition, and improve physical well-being in patients affected by cancer or heart disease.

  • cancer cachexia and weight loss support
  • obesity in patients with cardiovascular or joint disease
  • Improving nutritional status and metabolic balance

These studies show an interest in the broader metabolic impact of serious illness, not just the primary diagnosis.

Not possible to specify

Some studies at the site span more than one specialty or address supportive care questions that do not fit neatly into a single category. These trials may focus on surgical bleeding management, infection prevention, or other practical clinical needs, with the goal of improving safety and everyday treatment outcomes.

  • bleeding control and urgent procedure support
  • Infection prevention in vulnerable patient groups
  • Supportive and perioperative care research

Together, these projects add breadth to the site’s research profile and complement its disease-specific programs.

Site Overview

assignment
63
connected trials
corporate_fare
38
sponsors
science
135
IMPs

Activity Indicator

Last 6 months

7
Trials started
-22% vs previous period.
9
Trials started 6–12 months ago
63
Total trials linked
Highly Active
trending_downDeclining-22%
1
4
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 8 therapeutic areas and 15 of 135 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 120 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
34
Sponsors (total)
38
Active sponsors
25

Sponsor Network

Top 25 by active trials.

lock +24 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +11 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
63
Outperforms 96% of sites
public
Therapeutic diversity
9areas
Outperforms 93% of sites
groups
Sponsor diversity
38sponsors
Outperforms 97% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Osrodek Badan Klinicznych Przy Szpitalu Specjalistycznym Im. Ludwika Rydygiera W Krakowie Sp. z o.o.

lock Showing 1 of 63 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 135 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab11Unknown2018-08-242025-11-07

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.